Format

Send to

Choose Destination
See comment in PubMed Commons below
AAPS J. 2008;10(1):35-41. doi: 10.1208/s12248-007-9004-5. Epub 2008 Jan 25.

Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.

Author information

1
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20903-0002, USA. joyce.weaver@fda.hhs.gov

Abstract

The safety profile of newly approved drugs and therapeutic biologics is less well developed by pre-marketing clinical testing than is the efficacy profile. The full safety profile of an approved product is established during years of clinical use. For nearly 40 years, the FDA has relied on the voluntary reporting of adverse events by healthcare practitioners and patients to help establish the safety of marketed products. Epidemiologic studies, including case series, secular trends, case-control and cohort studies, are used to supplement the investigation of a safety signal. Ideally, active surveillance systems would supplement the identification and exploration of safety signals. The FDA has implemented a number of initiatives to help identify safety problems with drugs and continues to evaluate their efforts.

PMID:
18446503
PMCID:
PMC2751449
DOI:
10.1208/s12248-007-9004-5
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center